Invariant natural killer T (NKT) cells are a highly conserved subset of T lymphocytes expressing a semi-invariant T cell receptor (TCR), which is restricted to CD1d and specific for the glycosphingolipid antigen α-galactosylceramide. Their ability to secrete a variety of cytokines, which in turn modulate the activation of cells of both innate and acquired immune responses, suggests that invariant NKT cells exert a regulatory role mainly via indirect mechanisms. A relevant question is whether invariant NKT cells can directly help B cells. We document here that human invariant NKT cells are as efficient as conventional CD4+ Th0 lymphocytes in promoting proliferation of autologous memory and naive B lymphocytes in vitro, and in inducing immunoglobulin production. Help to B cells by invariant NKT cells is CD1d-dependent and delivered also in the absence of α-galactosylceramide, suggesting that NKT cells recognize an endogenous ligand presented by CD1d on B cells. The two major subsets of invariant NKT cells, CD4+ and double negative (CD4−CD8−), express comparable levels of CD40 ligand and cytokines, but differ in helper functions. Indeed, both subsets induce similar levels of B cell proliferation, whereas CD4+ NKT cells induce higher levels of immunoglobulin production. These results suggest a direct role for invariant NKT cells in regulating B lymphocyte proliferation and effector functions.
Skip Nav Destination
Article navigation
21 April 2003
Brief Definitive Report|
April 14 2003
CD1d-restricted Help To B Cells By Human Invariant Natural Killer T Lymphocytes
Grazia Galli,
Grazia Galli
1IRIS Research Center, Chiron Vaccines, 53100 Siena, Italy
Search for other works by this author on:
Sandra Nuti,
Sandra Nuti
1IRIS Research Center, Chiron Vaccines, 53100 Siena, Italy
Search for other works by this author on:
Simona Tavarini,
Simona Tavarini
1IRIS Research Center, Chiron Vaccines, 53100 Siena, Italy
Search for other works by this author on:
Luisa Galli-Stampino,
Luisa Galli-Stampino
1IRIS Research Center, Chiron Vaccines, 53100 Siena, Italy
Search for other works by this author on:
Claudia De Lalla,
Claudia De Lalla
2Cancer Immunotherapy and Gene Therapy Program DIBIT, H. San Raffaele Scientific Institute, 20132 Milano, Italy
Search for other works by this author on:
Giulia Casorati,
Giulia Casorati
2Cancer Immunotherapy and Gene Therapy Program DIBIT, H. San Raffaele Scientific Institute, 20132 Milano, Italy
Search for other works by this author on:
Paolo Dellabona,
Paolo Dellabona
2Cancer Immunotherapy and Gene Therapy Program DIBIT, H. San Raffaele Scientific Institute, 20132 Milano, Italy
Search for other works by this author on:
Sergio Abrignani
Sergio Abrignani
1IRIS Research Center, Chiron Vaccines, 53100 Siena, Italy
Search for other works by this author on:
Grazia Galli
1IRIS Research Center, Chiron Vaccines, 53100 Siena, Italy
Sandra Nuti
1IRIS Research Center, Chiron Vaccines, 53100 Siena, Italy
Simona Tavarini
1IRIS Research Center, Chiron Vaccines, 53100 Siena, Italy
Luisa Galli-Stampino
1IRIS Research Center, Chiron Vaccines, 53100 Siena, Italy
Claudia De Lalla
2Cancer Immunotherapy and Gene Therapy Program DIBIT, H. San Raffaele Scientific Institute, 20132 Milano, Italy
Giulia Casorati
2Cancer Immunotherapy and Gene Therapy Program DIBIT, H. San Raffaele Scientific Institute, 20132 Milano, Italy
Paolo Dellabona
2Cancer Immunotherapy and Gene Therapy Program DIBIT, H. San Raffaele Scientific Institute, 20132 Milano, Italy
Sergio Abrignani
1IRIS Research Center, Chiron Vaccines, 53100 Siena, Italy
Address correspondence to Sergio Abrignani, IRIS Research Center, Chiron Vaccines, Via Fiorentina 1, 53100 Siena, Italy. Phone: 39-0577-243032; Fax: 39-0577-243564; E-mail: [email protected]; or Paolo Dellabona, DIBIT, H. San Raffaele Scientific Institute, Via Olgettina 58, 20132 Milano, Italy. Phone: 39-02-26434727; Fax: 39-02-26434786; E-mail: [email protected]
*
Abbreviations used in this paper: α-GalCer, α-galactosylceramide; CFDA-SE, carboxyfluorescein-diacetate-succinimidyl ester; DN, double negative; inv. NKT, invariant NKT.
Received:
September 12 2002
Revision Received:
February 14 2003
Accepted:
February 26 2003
Online ISSN: 1540-9538
Print ISSN: 0022-1007
The Rockefeller University Press
2003
J Exp Med (2003) 197 (8): 1051–1057.
Article history
Received:
September 12 2002
Revision Received:
February 14 2003
Accepted:
February 26 2003
Citation
Grazia Galli, Sandra Nuti, Simona Tavarini, Luisa Galli-Stampino, Claudia De Lalla, Giulia Casorati, Paolo Dellabona, Sergio Abrignani; CD1d-restricted Help To B Cells By Human Invariant Natural Killer T Lymphocytes . J Exp Med 21 April 2003; 197 (8): 1051–1057. doi: https://doi.org/10.1084/jem.20021616
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement